Ask AI
ProCE Banner Activity

Expert Guidance on the Expanding Role of Immunotherapy in HNSCC: Downloadable Slides

Slideset Download
Download expert recommendations on the management of patients with head and neck cancer in this slideset from the HNSCC live meeting program.

Released: January 07, 2020

Expiration: January 05, 2021

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Merck Oncology

Faculty Disclosure

Primary Author

Barbara Burtness, MD

Anthony N. Brady Professor of Medicine
Chief Translational Officer
Associate Director, Translational Research
Chief, Head and Neck/Sarcoma Oncology
Co-Leader, Developmental Therapeutics Program
Yale Cancer Center
Yale School of Medicine
New Haven, Connecticut

Barbara Burtness, MD, has disclosed that she has received funds for research support from Advaxis, Bristol-Myers Squibb, Cue Biopharma, Formation Biosciences, GlaxoSmithKline, and Merck; consulting fees from Aduro, Alligator Biosciences, ALX Oncology, AstraZeneca, Celgene, Cue Biopharma, GlaxoSmithKline, Maverick, Merck, Nanobiotix, and MedImmune; and other financial or material support from Merck.

Cristina Rodriguez, MD

Professor
Division of Hematology/Medical Oncology
Department of Medicine
University of Washington
Member, Fred Hutchinson Cancer Center
Seattle, Washington

Cristina P. Rodriguez, MD, has disclosed that she has received consulting fees from Cue Biopharma and funds for research support paid to her institution from AstraZeneca, Ayala, and Bristol-Myers Squibb and that her spouse has received consulting fees from AstraZeneca and Merck and funds for research support paid to his institution from Acerta, AstraZeneca, Genentech, Incyte, Merck, Pharmacyclics, Portola, and Seattle Genetics.